TAE Technologies G Round Introduction July 2019

PRIVILEGED AND CONFIDENTIAL 1 Contents

TAE Technologies Overview 3 TAE Fusion 10 TAE Life Sciences 13 Disclaimer 17 Contact Information 18

PRIVILEGED AND CONFIDENTIAL 2 TAE Technologies Overview

PRIVILEGED AND CONFIDENTIAL 3 “I would like to see the development of to give an unlimited supply of clean energy and a switch to electric cars.”

Stephen Hawking

watch video online

PRIVILEGEDPRIVILEGED AND AND CONFIDENTIAL CONFIDENTIAL4 4 Vast fusion-incubated IP portfolio primed for commercialization Enables disruptive high-growth businesses

Game-changing targeted radiation cancer therapy

Revolutionary electric drivetrain platform for road, rail, air and sea

Advanced particle accelerators for fusion, POWER GENERATION POWER DISTRIBUTION medicine and more • Fusion R&D • Microgrids • Confinement licensing • Energy storage/buffering • control • Power switching • Consulting services • Power factor correction

PRIVILEGEDPRIVILEGED AND CONFIDENTIAL 5 Investment Opportunity Synopsis TAE is commercializing its intellectual property portfolio

• Inflection point in TAE’s evolution

• After over 1,100 patents filed and 20 years of R&D – starting to commercialize our technologies and realize accelerated revenues

• Multiple tiered opportunities that drive significant value creation around • Fusion power generation technology ($7 trillion cumulative market out to 2040) • Targeted radiation oncology ($30+ billion/yr market for head & neck tumors w/ 6% CAGR) • Mobility technology (e.g. $20+ billion/yr EV drivetrain market w/ 19% CAGR) • Power management technologies (e.g. $10+ billion/yr data center power market w/ 7% CAGR)

PRIVILEGED AND CONFIDENTIAL 6 Board, management and investors well-matched to opportunity Drawing on leadership from industry, technology and finance

Strong and engaged board including: • Former U.S. Secretary of Energy Ernest Moniz $600+ MILLION IN EQUITY • Former GE CEO & Chairman Jeff Immelt • Managing Director of Acadia Woods Partners Jeff Samberg CAPITAL INVESTED • CEO at Big Sky Michael Schwab from many of the most highly • Chairman of SmartDisck Corp. Addison Fischer experienced and sophisticated • NEA founder Dick Kramlich investors globally • Former Morgan Stanley CEO John Mack • Former NRC Chairman Dick Meserve

Independent Science Panel since 2006, comprised over the past dozen years of:

• Three Nobel Prize laureates • Five Maxwell Prize winners (the highest prize in plasma physics) • Two National Academy of Engineering members • Three JASON members • Concluded that residual risk to net energy is low

PRIVILEGED AND CONFIDENTIAL 7 Dominant TAE IP Position Vast patent portfolio & know-how as foundation for all TAE businesses

TAE Technologies global patent portfolio • Accelerating portfolio focused on fusion, life sciences and power 1100 management 1000 900 • 1,100+ filings, almost 650 granted 800 • Global IP protection in all critical 700 markets 600 500 • Wide range of know-how/trade 400 secrets 300 • Over 80% of IP portfolio 200 • Preserves key knowledge 100 and IP 0 • Consistent track record of 2011 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2012 2013 2014 2015 2016 2017 2018 innovation creates strong patent Pre-2000 Patents Granted (Cum) Patents Filed (Net) 2019 YTD position for decades ahead

PRIVILEGED AND CONFIDENTIAL 8 Value proposition for G-round investors Tremendous opportunity during last private round

• Last private round prior to IPO at >50% discount compared to enterprise IP valuation

• Senior preferred stock secured by valuation of TAE’s IP, TAE Life Sciences, and commercialization of power management/mobility

• 50% warrant coverage at same price exercisable upon Norman milestone

• Norman proof of science milestone to be completed in 2019

• Legacy-defining opportunity for investors

PRIVILEGED AND CONFIDENTIAL 9 TAE Fusion

PRIVILEGED AND CONFIDENTIAL 10 TAE’s fusion product is a confinement superiority platform – surpasses all other systems on physics performance and economic metrics

Clean, compact, safe, zero-carbon generation of affordable electricity

PRIVILEGED AND CONFIDENTIAL 11 watch video online

PRIVILEGED AND CONFIDENTIAL 12 TAE Life Sciences

PRIVILEGED AND CONFIDENTIAL 13 What is Cellular Targeted Particle Therapy? Boron Capture Therapy (BNCT)

• Target drug delivers boron-10 (10B) to cancer cells • Tumor irradiated with safe • 10B + neutron reaction emits particles that kill tumor cells • Healthy cells with no 10B are not damaged • Elegant combination of physics and biology

PRIVILEGED AND CONFIDENTIAL 14 BNCT – Radiation from within the cancer cell

Targeted Therapy Affordable & Effective for the Toughest Cancers • 3x killing efficacy • Predictable Physics • Infiltrative • Non toxic biologics • Metastatic • Single treatment • Recurrent/radio-resistant • Spares healthy tissue – Head & neck – Liver* – Brain – Lung* – Melanoma – Breast*

*Potential with new drugs

PRIVILEGEDPRIVILEGED AND AND CONFIDENTIAL CONFIDENTIAL15 15 Thank You PRIVILEGED AND CONFIDENTIAL 16 Disclaimer about this presentation

This presentation may contain “forward-looking statements” that refer to the Company’s potential, projected, estimated or forecasted goals, performance, results, or financial position. These forward-looking statements are based on the Company’s beliefs, expectations and assumptions and on information currently available to the Company. Although our management believes that the expectations reflected in our statements are reasonable, the Company makes no representation that the projected results will be achieved or occur, and actual results may differ materially from the Company’s expectations. There can be no assurance that the performance, results or achievements described in this presentation will occur within the time periods specified or at all. By their nature, these statements are subject to numerous uncertainties and risks, including factors beyond our control, that could cause actual results, performance or achievement to differ materially and adversely from those anticipated or implied in the statements. It is not possible for us to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results or outcomes to differ materially from those contained in any forward- looking statements we may make. Recipients are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date such statements are made and should not be construed as statements of fact. Except as required by law, the Company does not assume any obligation to update forward-looking statements as a result of new information, subsequent events, or any other circumstances after the date hereof, or to reflect the occurrence of unanticipated events.

PRIVILEGEDPRIVILEGED AND CONFIDENTIAL 17 PROPRIETARY AND CONFIDENTIAL © TAE Technologies, Inc. All rights reserved.

ROCK LAKE ADVISORS Bahnhofstrasse 30 | 6300 Zug, Switzerland

JOHN C. COOK | Chairman [email protected]

JONATHAN P. TORETTA | President [email protected]

PRIVILEGED AND CONFIDENTIAL 18